1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6BA67D772C3C9555A00258B820054F3D5
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/BA67D772C3C9555A00258B820054F3D5?OpenDocument
18
19OpenDocument
2018.97.9.169
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Product Launch » Market Entry and Oncology

Document Excerpt: KEYTRUDA Case Study: How Merck Used Bold Indications Planning Coupled with Expansive Clinical Trials to Lift a Second-To-Market Product into the Annals of Blockbuster Launch History

DB Image

ID: MD-920


Features:

42 Info Graphics

19 Data Graphics

230+ Metrics

7 Narratives


Pages/Slides: 4


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt".

To return to the study abstract to purchase the full study -
click here

This excerpt includes research findings and metrics from document #5820 “KEYTRUDA Case Study: How Merck Used Bold Indications Planning Coupled with Expansive Clinical Trials to Lift a Second-To-Market Product into the Annals of Blockbuster Launch History”.

Industries Profiled:
Pharmaceutical; Health Care; Biotech; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Merck; Advaxis; Ascentage Pharma; Astellas; AstraZeneca; Bristol-Myers Squibb; Cold Genesys; Compass Therapeutics; Eisai; Eli Lilly and Company; ENB Therapeutics; Fusion Pharmaceuticals; Genome & Company; Gilead Sciences; Hanmi Pharmaceuticals; IDEAYA Biosciences; Incyte; Medicenna Therapeutics; Microbiotica; OncoSec Medical; Ono Pharmaceuticals; Organon; Pfizer; PharmAbcine; PMV Pharmaceuticals; Sanofi; Schering-Plough; Seagen; Seven and Eight BioPharmaceuticals; TetraLogic Pharmaceuticals; Viralytics; Wellmarker Bio

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.